Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
Provided By GlobeNewswire
Last update: Nov 14, 2024
-- Transformative Financing worth up to $275 million from Top-Tier Institutional Healthcare Investors --
-- Advancement of IkT-001Pro into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension --
Read more at globenewswire.com1.8
-0.04 (-2.17%)
Find more stocks in the Stock Screener
IKT Latest News and Analysis
